Invivyd, Inc. (IVVD) — SEC Financial Statements & Analysis

Invivyd, Inc. (IVVD) is a biological products, (no diagnostic substances) company, incorporated in DE. Invivyd, Inc. trades on Nasdaq as: IVVD. Invivyd, Inc. (IVVD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Invivyd, Inc. carries a market cap of $279.42M, a P/E ratio of -2.60x, a P/B ratio of 1.54x, a P/S ratio of 4.79x, an enterprise value of $119.34M, and an EV/EBITDA multiple of -1.06x. On profitability, it posts a gross margin of 98.89%, an operating margin of -192.81%, a net margin of -183.90%, a Return on Equity (ROE) of -95.89%, a Return on Assets (ROA) of -69.69%, and a Return on Invested Capital (ROIC) of -726.60%. Per share, it reports EPS of $-0.33, diluted EPS of $-0.33, free cash flow per share of $-0.34, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 26.30% year-over-year, net income growth of -2.54% year-over-year, and EPS growth of -63.50% year-over-year. On the balance sheet, it maintains a current ratio of 5.87x, a quick ratio of 5.52x, working capital of $151.08M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.17, free cash flow of $-109.66M (TTM), and net debt of $-160.08M. Figures sourced from SEC EDGAR.

Market Cap

$279.42M

P/E TTM

-2.60x

EPS TTM

$-0.33

P/B TTM

1.54x

ROE TTM

-95.89%

ROA TTM

-69.69%

Debt To Equity

0.21x

Free Cash Flow TTM

$-109.66M

Net Revenue TTM Growth 1Y

26.30%

Data as of 2026-06-30 · Source: SEC EDGAR